Analyst Information

 

David Amsellem

Sr. Research Analyst

David Amsellem

 David Amsellem is a managing director and senior research analyst at Piper Sandler covering specialty pharmaceuticals. Prior to joining Piper Sandler in 2008, Amsellem spent five years at Friedman Billings Ramsey, where he was a senior research analyst covering small- and mid-cap pharmaceuticals from 2006-08 and a senior associate on the biotechnology equity research team from 2003-06. Amsellem has more than 15 years of Wall Street experience focused on the biopharmaceuticals space, with experience in life sciences investment and merchant banking prior to moving to the sell-side. Amsellem earned a bachelor’s degree from Cornell University.

Associates:

Zachary Sachar
Research Analyst
Universe Coverage:
Healthcare:   Specialty Pharmaceuticals
ADMSAdamas Pharmaceuticals, Inc.
AKRXAkorn, Inc.
AGNAllergan plc
AMRXAmneal Pharmaceuticals Inc.
AMPHAmphastar Pharmaceuticals, Inc.
ATRSAntares Pharma, Inc.
AVDLAvadel Pharmaceuticals plc
BXRXBaudax Bio Inc.
BHCBausch Health Companies
BDSIBioDelivery Sciences International, Inc.
CARACara Therapeutics Inc.
COLLCollegium Pharmaceutical, Inc.
EGRXEagle Pharmaceuticals Inc.
ENDPEndo International plc
HZNPHorizon Therapeutics
JAZZJazz Pharmaceuticals plc
MNKMallinckrodt
MNLOMenlo Therapeutics Inc.
MYLMylan N.V.
NBIXNeurocrine Biosciences Inc.
OPTNOptiNose, Inc.
PCRXPacira Biosciences, Inc.
RVNCRevance Therapeutics, Inc.
SUPNSupernus Pharmaceuticals, Inc.
TEVATeva Pharmaceutical Industries Limited
XERSXeris Pharmaceuticals, Inc.